Basel, Switzerland, October 30, 2013 – Novartis announced today it has filed a Citizen Petition with the US Food and Drug Administration (FDA), urging the Agency to require that a biosimilar share the same INN as the reference product. Novartis files Citizen Petition with FDA, urging uniform approach to use of international nonproprietary names (INN) for […]
New Relationship Gives Customers More Options for Managing Their Supply Chains MEMPHIS, Tenn., and Dublin, Ohio, Oct. 29, 2013 – FedEx Corp. (NYSE: FDX) and Cardinal Health, (NYSE:CAH) announced today that they have formed a strategic alliance that will enable the companies to leverage their market-leading capabilities to provide 3PL solutions. By combining the global […]
Reduction of Viral Load at or Below Limit of Detection Ongoing at 14 Weeks Additional Presentations of Preclinical Data at Annual Meeting of European Society of Gene and Cell Therapy (ESGCT) RICHMOND, Calif., Oct. 28, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new data demonstrating sustained control of HIV viral load (VL) at […]
Every 30 seconds, someone in the US is hospitalized for heart failure1; mobile solutions could play a role to help manage this disease Novartis Mobile Health Challenge attracted more than 200 companies and developers who competed for cash prizes Winning mobile solutions designed to provide caregivers with novel tools to navigate daily challenges of caring […]
LAVAL, Quebec, Oct. 28, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has entered into a settlement agreement with Anacor Pharmaceuticals to resolve all outstanding disputes between them, including the previously disclosed disputes involving Anacor and Valeant’s subsidiaries, Dow Pharmaceutical Sciences, Inc. (Dow) and Medicis Pharmaceutical Corporation. […]
Stockholm, October 25 – Elekta announced today that Niklas Savander has been appointed as its next President and Chief Executive Officer, effective May 1, 2014. Niklas Savander will succeed Tomas Puusepp, who will continue with Elekta as a working member of its Board of Directors focusing on strategic matters and market-developments per the same date. […]
Study Data Shows Cialis 5 mg Initiated with Finasteride Provides Significantly Greater Improvements in Urinary Symptoms of Benign Prostatic Hyperplasia than Placebo with Finasteride INDIANAPOLIS, Oct. 25, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a product label addition for CIALIS to include data from a 26-week study that showed […]
SUNNYVALE, Calif., Oct. 24, 2013 (GLOBE NEWSWIRE) — In two independent analyses comparing robotic-assisted surgery and open surgery performed on patients with urologic cancers, researchers found that robotic-assisted surgery results in fewer overall complications during and after surgery, less blood loss and shorter length of hospital stay. In the first analysis, which was published in this month’s […]
One-time single eye injection of Jetrea® recognized as clinically and cost-effective treatment for eligible patients with vitreomacular traction, including macular hole Jetrea® is the first and only approved pharmacological treatment in the UK for this sight-threatening condition Vitreomacular traction with macular hole is an age-related eye condition that can cause loss of vision and impaired […]
INDIANAPOLIS, Oct. 23, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy. “We are very pleased that the FDA has […]